130 related articles for article (PubMed ID: 1657201)
1. CA 195: a new monoclonal antibody-defined Lea blood group-related tumor marker in patients with epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Prontera C; Moretti L; Pellagatta L; Bianchi R; Fioretti P
J Nucl Biol Med (1991); 1991; 35(1):33-7. PubMed ID: 1657201
[TBL] [Abstract][Full Text] [Related]
2. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
3. The serum concentrations of TAG-72 antigen measured with CA 72-4 IRMA in patients with ovarian carcinoma. Preliminary data.
Gadducci A; Ferdeghini M; Ceccarini T; Prontera C; Facchini V; Bianchi R; Fioretti P
J Nucl Med Allied Sci; 1989; 33(1):32-6. PubMed ID: 2746365
[TBL] [Abstract][Full Text] [Related]
4. [Significance of CA 125 antigen levels in patients with ovarian cancer].
Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
6. Role of Ca 125 as tumor marker in ovarian carcinoma.
Krebs HB; Goplerud DR; Kilpatrick SJ; Myers MB; Hunt A
Obstet Gynecol; 1986 Apr; 67(4):473-7. PubMed ID: 3008052
[TBL] [Abstract][Full Text] [Related]
7. [Application of monoclonal antibody OC 125 in gynecological oncology].
Wu AR; Wang EY; Wang XX; Jia XH; Li L
Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):132-6. PubMed ID: 3208653
[TBL] [Abstract][Full Text] [Related]
8. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
Gan To Kagaku Ryoho; 1994 May; 21(6):823-32. PubMed ID: 8185340
[TBL] [Abstract][Full Text] [Related]
9. [Tumor marker CA 72-4 in ovarian cancer in comparison with CA 125 and D-dimer].
Schelling M; Jänicke F; Senekowitsch R; Lörken A
Gynakol Rundsch; 1991; 31 Suppl 2():286-9. PubMed ID: 1665138
[No Abstract] [Full Text] [Related]
10. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous measurement of CA 125, CA 19-9, tissue polypeptide antigen, and immunosuppressive acidic protein to predict recurrence of ovarian cancer.
Kamiya N; Mizuno K; Kawai M; Kano T; Furuhashi Y; Tomoda Y
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):417-21. PubMed ID: 2381619
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
[TBL] [Abstract][Full Text] [Related]
13. Significance of some tumor markers in differential diagnosis of ovarian tumor.
Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
[TBL] [Abstract][Full Text] [Related]
14. CA 125 and carcinoembryonic antigen levels in cyst fluid, ascites and serum of patients with ovarian neoplasms.
Harłozińska A; Bar JK; Gawlikowski W; Richter R; Cisło M
Ann Chir Gynaecol; 1991; 80(4):368-75. PubMed ID: 1667567
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
Peters-Engl C; Medl M; Ogris E; Leodolter S
Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
[TBL] [Abstract][Full Text] [Related]
16. Preoperative serum tumor-associated antigen levels in women with pelvic masses.
Soper JT; Hunter VJ; Daly L; Tanner M; Creasman WT; Bast RC
Obstet Gynecol; 1990 Feb; 75(2):249-54. PubMed ID: 2300353
[TBL] [Abstract][Full Text] [Related]
17. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer.
Einhorn N; Bast RC; Knapp RC; Tjernberg B; Zurawski VR
Obstet Gynecol; 1986 Mar; 67(3):414-6. PubMed ID: 2418395
[TBL] [Abstract][Full Text] [Related]
18. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer.
Scambia G; Panici PB; Baiocchi G; Perrone L; Iacobelli S; Mancuso S
Anticancer Res; 1988; 8(4):761-4. PubMed ID: 3178164
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of tumor-associated mucin-type glycoprotein CA 54/61 in ovarian cancers: comparison with CA 125.
Suzuki M; Sekiguchi I; Tamada T
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):422-7. PubMed ID: 2381620
[TBL] [Abstract][Full Text] [Related]
20. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
Suzuki M; Ohwada M; Aida I; Tamada T; Hanamura T; Nagatomo M
Obstet Gynecol; 1993 Dec; 82(6):946-50. PubMed ID: 8233270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]